조현병 환자의 개인적, 사회적 기능상태의 예측인자 = Factors Predicting Personal and Social Performance in Schizophrenia Patients

다국어 초록 (Multilingual Abstract)

Objectives : Schizophrenia is a chronic psychiatric disorder characterized by its debilitating course. It leads to personal and social dysfunctions, burdening patients and guardians heavily. Enhancing functional outcome is a major treatment goal, but pharmacotherapy alone is usually not enough. Hence, it is important to reveal clinical factors that can predict personal and social performance in schizophrenia patients. Analyze factors influencing personal and social performance in schizophrenia patients.
Methods : 66 schizophrenia patients from three University hospitals in Korea were enrolled, completing clinical scales between January 2008 and December 2009. 38 patients dropped out during follow up. 28 patients were included in the final study. Personal and social performance was measured using the Personal and Social Performance scale (PSP) since January 2015. Correlation and multiple regression analyses were performed to reveal associations between demographic and clinical factors and PSP.
Results : Correlation analyses resulted in statistically significant correlations between CGI-S (r=-0.646, p＜0.01), PANSS (r= -0.419, p＜0.05), KISP (r=-0.523, r＜0.01), KmSWN (r=0.388, p＜0.05), Trail making B (r=0.608, p＜0.01), KDAI (r=0.608, p＜0.01), and PSP. Stepwise multiple regression analyses showed significant models with CGI-S (β=-0.485, p＜0.01), and KDAI (β=0.423, p＜0.01).
Conclusion : Our results show that attitude toward drugs and symptom severity affect a patient’s personal and social performance most prominently. We advise to focus on patient education to reinforce attitude toward drugs, and to concentrate on reducing symptom severity to enhance personal and social performance in schizophrenia patients.

참고문헌 (Reference)

1 윤진상, "항정신병 약물치료하에서주관적 안녕감을 평가하는 한 국형 척도의 개발" 987-989, 2000

2 윤보현, "한국판 약물태도 척도의 심리측정적 특성" 대한정신약물학회 16 (16): 480-487, 2005

3 정희연, "한국판 리버풀 항정신병약물 부작용 평가 척도(LUNSERS)의 표준화 연구 - 리버풀 항정신병약물 부작용 평가 척도 -" 대한신경정신의학회 41 (41): 138-145, 2002

4 이정구, "한국판 Personal and Social Performance 척도 (K-PSP)의 표준화 연구" 대한정신약물학회 17 (17): 497-506, 2006

5 조다함, "한국인 조현병 환자에서 흡연과 사회인구학적, 임상적 특성과의 관계" 대한신경정신의학회 51 (51): 255-262, 2012

6 김용구, "한국어판 정신분열병의 캘거리 우울증 척도의 신뢰도 및 타당도 연구" 대한신경정신의학회 44 (44): 446-455, 2005

7 문영선, "약물 교체가 필요한 조현병 환자에서 Paliperidone Extended Release로의 교체 후 유효성과 안전성에 관한 분석" 대한정신약물학회 23 (23): 97-106, 2012

8 Green MF, "What are the functional consequences of neurocognitive deficits in schizophrenia?" 153 : 321-330, 1996

9 Wechsler D, "Wechsler adult intelligence scale-fourth" Pearson 2008

10 Leifker FR, "Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel" 37 : 334-343, 2011

11 Mahurin RK, "Trail making test errors and executive function in schizophrenia and depression" 20 : 271-288, 2006

12 Mahurin RK, "Trail making test errors and executive function in schizophrenia and depression" 20 : 271-288, 2006

13 Perianez JA, "Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: Sample comparisons and normative data" 22 : 433-447, 2007

14 Lysaker PH, "Toward understanding the insight paradox: Internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders" 33 : 192-199, 2007

15 Rabinowitz J, "To what extent do the PANSS and CGI-S overlap?" 26 : 303-307, 2006

16 Carbon M, "Thinking and acting beyond the positive:the role of the cognitive and negative symptoms in schizophrenia" 19 : 38-53, 2014

17 Remington G, "The use of electronic monitoring (MEMS®) to evaluate antipsychotic compliance in outpatients with schizophrenia" 90 : 229-237, 2007

18 Norman RMG, "The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale" 102 : 303-309, 2000

19 Evans JD, "The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients" 53 : 422-430, 2003

20 Racenstein JM, "The relationship between positive symptoms and instrumental work functioning in schizophrenia: A 10 year follow-up study" 56 : 95-103, 2002

21 Juckel G, "The new approach: psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia" 21 : 630-639, 2008

22 Brissos S, "The importance of measuring psychosocial functioning in schizophrenia" 10 : 18-18, 2011

23 Velligan DI, "The functional significance of symptomatology and cognitive function in schizophrenia" 25 : 21-31, 1997

24 Davies LM, "The economic burden of schizophrenia" 14 : 522-525, 1990

25 Crowe SF, "The differential contribution of mental tracking, cognitive flexibility, visual search, and motor speed to performance on Parts A and B of the Trail Making Test" 54 : 585-591, 1998

26 Awad AG, "The burden of schizophrenia on caregivers" 26 : 149-162, 2008

27 Brissos S, "The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients" 47 : 1077-1086, 2012

28 Zimet GD, "The Multidimensional Scale of Perceived Social Support" 52 : 30-41, 1988

29 Endicott J, "The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance" 33 : 766-, 1976

30 Busner J, "The Clinical Global Impressions scale: errors in understanding and use" 50 : 257-262, 2009

31 Haro JM, "The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia" 107 : 16-23, 2003

32 Markova IS, "The Assessment of Insight in Clinical-Psychiatry-a New Scale" 86 : 159-164, 1992

33 Malla AK, "Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis" 32 : 1109-1119, 2002

34 Ventura J, "Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis" 113 : 189-199, 2009

35 Naber D, "Subjective well-being under neuroleptic treatment and its relevance for compliance" 111 : 29-34, 2005

36 Priebe S, "Social outcomes in schizophrenia" 191 : s15-s20, 2007

37 Lysaker PH, "Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition" 2 : 1-, 2004

38 Meesters PD, "Social Functioning Among Older Community-Dwelling Patients With Schizophrenia: A Review" 18 : 862-878, 2010

39 Excellence NIfC, "Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care" National Institute for Clinical Excellence 2002

40 Tandon R, "Schizophrenia, “just the facts’ 4. Clinical features and conceptualization" 110 : 1-23, 2009

41 Goldman HH, "Revising axis V for DSM-IV:a review of measures of social functioning" 149 : 1148-1156, 1992

42 DeQuardo JR, "Review Do atypical antipsychotic medications favorably alter the long-term course of schizophrenia?" 32 : 229-242, 1998

43 Nasrallah H, "Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia" 161 : 213-224, 2008

44 Karadayı G, "Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia" 52 : 701-707, 2011

45 Ritsner MS, "Quality of life impairment in schizophrenia, mood and anxiety disordersed" Springer 173-226, 2007

46 Elis O, "Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions" 33 : 914-928, 2013

47 Kawata AK, "Psychometric properties of the Personal and Social Performance scale (PSP) among individuals with schizophrenia living in the community" 17 : 1247-1256, 2008

48 Eack SM, "Psychiatric symptoms and quality of life in Schizophrenia: A meta-analysis" 33 : 1225-1237, 2007

49 Yamauchi K, "Predictors of subjective and objective quality of life in outpatients with schizophrenia" 62 : 404-411, 2008

50 Novick D, "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia" 176 : 109-113, 2010

51 Bowie CR, "Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder" 2010

52 Arango C, "Pharmacological approaches to treating negative symptoms: A review of clinical trials" 150 : 346-352, 2013

53 Goodman AB, "Paranoid Schizophrenia-Prognosis under Dsm-Ii and Dsm-Iii-R" 30 : 259-266, 1989

54 Wyatt RJ, "Neuroleptics and the Natural Course of Schizophrenia" 17 : 325-351, 1991

55 Woon PS, "Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia" 34 : 463-468, 2010

56 Rocca P, "Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real world-setting" 218 : 284-289, 2014

57 Ascher-Svanum H, "Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care" 67 : 453-460, 2006

58 Lambert TJR, "Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement" 18 : 405-411, 2003

59 Szoke A, "Longitudinal studies of cognition in schizophrenia: metaanalysis" 192 : 248-257, 2008

60 황순택, "K-WAIS-IV 표준화-신뢰도와 타당도 (초)" 140-140, 2012

61 Nakagami E, "Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: Testing mediator and moderator effects" 105 : 95-104, 2008

62 McCabe R, "Insight, global neuropsychological functioning, and symptomatology in chronic schizophrenia" 190 : 519-525, 2002

63 Stefanopoulou E, "Insight, Global Functioning and Psychopathology Amongst In-patient Clients with Schizophrenia" 80 : 155-165, 2009

64 Buckley PF, "Insight and its relationship to violent behavior in patients with schizophrenia" 161 : 1712-1714, 2004

65 Wölwer W, "Impaired Trail-Making Test-B performance in patients with acute schizophrenia is related to inefficient sequencing of planning and acting" 36 : 407-416, 2002

66 Matheson SL, "How much do we know about schizophrenia and how well do we know it? Evidence from the Schizophrenia Library" 44 : 3387-3405, 2014

67 Hall RCW, "Global Assessment of Functioning-a Modified Scale" 36 : 267-275, 1995

68 Martinez-Aran A, "Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome" 71 : 39-46, 2002

69 Hutton SB, "Executive function in first-episode schizophrenia" 28 : 463-473, 1998

70 Kinon BJ, "Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia" 35 : 581-590, 2010

71 Guy W, "ECDEU Assessment Manual for Psychopharmacology:1976" National Institute of Mental Health 1976

72 Schwartz RC, "Does insight affect longterm inpatient treatment outcome in chronic schizophrenia?" 38 : 283-288, 1997

73 Morosini PL, "Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS)to assess routine social funtioning" 101 : 323-329, 2000

74 Lambert M, "Current issues in schizophrenia: Overview of patient acceptability, functioning capacity and quality of life" 18 : 5-17, 2004

75 Mohamed S, "Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia" 35 : 336-346, 2009

76 Hofer A, "Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder" 256 : 246-255, 2006

77 McGurk SR, "Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment" 2003

78 Markova IS, "Assessment of insight in psychosis: a re-standardization of a new scale" 119 : 81-88, 2003

79 Kim J, "Assessing the reliability and validity of the Korean version of the Revised Insight Scale for Psychosis (KISP)" 7 : 15-22, 2004

80 Baloush-Kleinman V, "Adherence to antipsychotic drug treatment in early-episode schizophrenia: A six-month naturalistic follow-up study" 130 : 176-181, 2011

81 Seo EH, "A normative study of the Trail Making Test in Korean elders" 21 : 844-852, 2006

82 Hogan TP, "A Self-Report Scale Predictive of Drug Compliance in Schizophrenics-Reliability and Discriminative Validity" 13 : 177-183, 1983

83 Day JC, "A Self-Rating Scale for Measuring Neuroleptic Side-Effects-Validation in a Group of Schizophrenic-Patients" 166 : 650-653, 1995

84 Addington D, "A Depression Rating-Scale for Schizophrenics" 3 : 247-251, 1990